Evidence map›Paper›PMID 32930996›Full record

ArticleNeurotoxicity research2021

Promotion of Mitochondrial Protection by Emodin in Methylglyoxal-Treated Human Neuroblastoma SH-SY5Y Cells: Involvement of the AMPK/Nrf2/HO-1 Axis.

Marcos Roberto de Oliveira, Izabel Cristina Custódio de Souza, Flávia Bittencourt Brasil

Abstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Marcos Roberto de OliveiraGrupo de Estudos em Neuroquímica e Neurobiologia de Moléculas Bioativas, Universidade Federal de Mato Grosso (UFMT), Av. Fernando Corrêa da Costa, 2367, CEP, Cuiaba, MT, 78060-900, Brazil. mrobioq@gmail.com.ORCID http://orcid.org/0000-0003-2414-6605
Izabel Cristina Custódio de SouzaPrograma de Pós-Graduação em Bioquímica e Bioprospecção (PPGBBIO), Centro de Ciências Químicas, Farmacêuticas e de Alimentos (CCQFA), Instituto de Biologia, Universidade Federal de Pelotas (UFPel), Pelotas, RS, Brazil.
Flávia Bittencourt BrasilDepartamento de Ciências da Natureza, Campus Universitário de Rio das Ostras - Universidade Federal Fluminense (UFF), Rio de Janeiro, Brazil.
Universidade Federal de Mato Grosso · BRUniversidade Federal de Pelotas · BRUniversidade Federal Fluminense · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 460903/2014-4Conselho Nacional de Desenvolvimento Científico e Tecnológico Bolsista Produtividade PQ2 fellow protocol number 301273/2018-9Conselho Nacional de Desenvolvimento Científico e Tecnológico Edital Universal 2016 protocol number 400216/2016-7
6 · The paper itself

Abstract

Mitochondrial dysfunction is part of the mechanism of several human diseases. This negative circumstance may be induced by certain toxicants, as methylglyoxal (MG). MG is a reactive dicarbonyl presenting both endogenous and exogenous sources and is also able to induce protein cross-linking and glycation. Emodin (EM; 1,3,8-trihydroxy-6-methylanthracene-9,10-dione; C

Indexed as

Adenylate KinaseCell Line, TumorEmodinHeme Oxygenase-1HumansMitochondriaNF-E2-Related Factor 2PyruvaldehydeSignal TransductionAdenylate KinaseEmodinHeme Oxygenase-1HMOX1 protein, humanNFE2L2 protein, humanNF-E2-Related Factor 2PyruvaldehydeAntioxidantBioenergeticsEmodinMethylglyoxalMitochondriaSH-SY5Y cells

Identifiers

PMID32930996
OpenAlexW3087335841

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.